Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Prana Biotechnology Ltd Sponsored ADR (PRAN) Report Updated: Aug 12, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Prana Biotechnology Ltd Sponsored ADR (PRAN)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
service keys

Prana Biotechnology Ltd Sponsored ADR© quotemedia

Company Profile

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate is PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company was founded in 1997 and is based in Parkville, Australia.